Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 227 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sucrose Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

NCT01669603
View directory record Official record
Conditions
Common Cold
Interventions
Bifidobacterium lactis Bl-04, Placebo, Rhinovirus
Dietary Supplement · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 2, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Not applicable Interventional

FODMAP Reintroduction in Irritable Bowel Syndrome

NCT03245645
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Mixed Bowel Habits
Interventions
Dietary Intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 2, 2026, 10:51 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

NCT06967181
View directory record Official record
Conditions
Mumps
Interventions
CVM150, CVM26, Placebo
Biological · Other
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 2, 2026, 10:51 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

NCT03893045
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glucose and Motivation States

NCT07255183
View directory record Official record
Conditions
Motivation
Interventions
Exercise, Sugar Drink, Non-sugar beverage
Behavioral · Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

NCT00981045
View directory record Official record
Conditions
Iron Deficiency Anemia, Impaired Renal Function
Interventions
Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Cranberry Beverage on Intestinal Permeability and Gastrointestinal Function in Generally Healthy Adults

NCT03957239
View directory record Official record
Conditions
Intestinal Permeability, Gastrointestinal Function
Interventions
Cranberry Beverage, Control Beverage
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 2, 2026, 10:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

NCT01220128
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 4 Interventional

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

NCT00223964
View directory record Official record
Conditions
Anemia
Interventions
Ferrlecit (sodium ferric gluconate complex in sucrose injection)
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
2 Years to 16 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314
View directory record Official record
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 2, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)

NCT05992688
View directory record Official record
Conditions
Adiposity, Insulin Sensitivity, Weight Gain, Blood Pressure, Lipoproteins
Interventions
Sucrose sweetened beverage, Stevia sweetened beverages, Calorie free flavored water beverage
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 12 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 2, 2026, 10:51 AM EDT
Completed No phase listed Observational Results available

Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)

NCT01914003
View directory record Official record
Conditions
Congenital Sucrase-isomaltase Deficiency (CSID)
Interventions
Not listed
Lead sponsor
QOL Medical, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Los Angeles, California • Oakland, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 2, 2026, 10:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sorting of Oral Sensations

NCT02390180
View directory record Official record
Conditions
Taste Qualities, Primary Tastes
Interventions
Tasting solutions
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 2, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 2, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.

NCT07650058
View directory record Official record
Conditions
Healthy Participants
Interventions
High-Glycemic Breakfast Containing Cereal and Fresh Mango, High-Glycemic Breakfast Containing Cereal and Table Sugar
Other
Lead sponsor
Ball State University
Other
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

NCT03064347
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sucrose plus Whole Milk Powder in Enteric Coating, Non coated Sucrose plus Whole Milk, Sucrose in Enteric Coating, Sucrose with Separate Enteric Coating Materials, Whey Protein in Enteric Coating, Whey Protein with Separate Enteric Coating Materials, Pea Protein in Enteric Coating, Pea Protein with Separate Enteric Coating Materials
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 2, 2026, 10:51 AM EDT
Approved For Marketing No phase listed Expanded access

EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML

NCT02533115
View directory record Official record
Conditions
Secondary AML
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 2, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional

Maternal Immunization To Prevent Infant Otitis Media

NCT00617682
View directory record Official record
Conditions
Otitis Media
Interventions
PNCRM9, Placebo comparator
Biological
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bloomington, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Sep 2, 2026, 10:51 AM EDT